RxDoctor Payments Data

Rasha Ghurani, MD

Internal Medicine · Dallas, TXNPI 1699741785

Payments from drug & device makers

$15,399in general payments, 2019–2025

Across 624 payments — averaging $24.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$8K
  • Gilead$4K
  • Johnson & Johnson$2K
  • Merck$982
  • Janssen Products, LP$383
  • Novo Nordisk$208
  • plus $816 from 15 others

What the payments were for

  • Consulting fees$1,3809%
  • Food & beverage$13,88090%
  • Education$1391%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,399 in reported general payments places this provider in the 95th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$35,268
Medicare patients
143
Services billed
368

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala80$295,646
DovatoDolutegravir Sodium/Lamivudine75$229,655
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf33$150,527
TivicayDolutegravir Sodium54$128,510
TriumeqAbacavir/Dolutegravir/Lamivudi35$124,833
DescovyEmtricitabine/Tenofov Alafenam47$104,005
PrezcobixDarunavir/Cobicistat40$84,135
GenvoyaElviteg/Cob/Emtri/Tenof Alafen21$68,118
OzempicSemaglutide18$17,865
Abacavir-LamivudineAbacavir Sulfate/Lamivudine12$5,950
Novolog Mix 70-30 FlexpenInsulin Aspart Prot/Insuln Asp13$1,580
Gabapentin34$301
Hydroxyzine Hcl11$291
Metoprolol Succinate11$222
Levetiracetam11$216

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Viiv Healthcare CompanyDovato, Tivicay, Triumeq$7,622$482,998164 claims
GileadBiktarvy, Descovy, Genvoya$3,569$467,769148 claims
Janssen Products, LPSymtuza$383$150,52733 claims
Johnson & JohnsonPrezcobix$1,820$84,13540 claims
Novo NordiskOzempic$208$17,86518 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Dallas

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →